Skip to main content
September 11

Health Subcommittee Vote on H.R. 1206, H.R. 6118, H.R. 1063, H.R. 6163, H.R. 4124, H.R. 733

2123 Rayburn, 2:00am

Health Subcommittee Vote on H.R. 1206, H.R. 6118, H.R. 1063, H.R. 6163, H.R. 4124, H.R. 733

Background Documents and Information:

The health care law’s misguided Medical Loss Ratio (MLR) mandate violates President Obama’s long repeated promise that “if you like the plan you have, you can keep it.” During a September 15, 2011, hearing, witnesses testified that the MLR regulations have created a “desperate economic situation” for a half-million insurance agents and brokers. This requirement could force agents to leave the market or significantly limit their plan offerings, creating a level of disruption that would quickly destabilize the market and threaten the ability of insurers to continue offering plans. H.R. 1206 would exclude from the calculation of the MLR commissions paid to independent insurance brokers and agents who work to find individuals and small businesses affordable insurance options.

H.R. 6118 would give the Centers for Medicare and Medicaid Services much needed regulatory flexibility to enforce prohibitions against improper referrals of proficiency testing under the Clinical Laboratory Improvement Amendments (CLIA).

H.R.1063 would create efficiencies in the Medicare Secondary Payer program to speed up the process of returning money to the Medicare Trust Fund while reducing costly legal barriers for both large and small employers.

H.R. 6163 allows NIH to fund pediatric research networks comprised of a consortia of cooperating institutions that will cooperate in conducting research on conditions and disease affecting pediatric populations.

H.R. 4124 would provide demonstration grants to states with a shortage of emergency medical technicians (EMTs) to streamline state-licensing requirements for military veteran EMTs to prevent unnecessary duplication in training.

H.R. 733 directs the National Cancer Institute to establish a scientific framework with respect to research of recalcitrant cancers with low survival rates in order to advance diagnosis and treatment. The scientific framework will include a review of the current research, coordinate new initiatives, and identify unanswered medical and scientific questions.  


Markup Notice

Background Memo